Literature DB >> 29055034

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Stephen Ph Alexander1, Doriano Fabbro2, Eamonn Kelly3, Neil V Marrion3, John A Peters4, Elena Faccenda5, Simon D Harding5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5.   

Abstract

The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13877/full. Enzymes are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
© 2017 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29055034      PMCID: PMC5650666          DOI: 10.1111/bph.13877

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  2 in total

1.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

2.  Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).

Authors:  Kenneth D Rice; Naing Aay; Neel K Anand; Charles M Blazey; Owen J Bowles; Joerg Bussenius; Simona Costanzo; Jeffry K Curtis; Steven C Defina; Larisa Dubenko; Stefan Engst; Anagha A Joshi; Abigail R Kennedy; Angie I Kim; Elena S Koltun; Julie C Lougheed; Jean-Claire L Manalo; Jean-Francois Martini; John M Nuss; Csaba J Peto; Tsze H Tsang; Peiwen Yu; Stuart Johnston
Journal:  ACS Med Chem Lett       Date:  2012-04-09       Impact factor: 4.345

  2 in total
  555 in total

1.  The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease.

Authors:  Xiaoying Lian; Xiaoyuan Wu; Zhongxin Li; Yingjie Zhang; Kangkang Song; Guangyan Cai; Qinggang Li; Shupeng Lin; Xiangmei Chen; Xue-Yuan Bai
Journal:  Br J Pharmacol       Date:  2019-01-10       Impact factor: 8.739

2.  Knockdown of the transcript of ERK in the brain modulates hypothalamic neuropeptide-mediated appetite control in amphetamine-treated rats.

Authors:  Ching-Han Yu; Yih-Shou Hsieh; Pei-Ni Chen; Jeng-Rung Chen; Dong-Yih Kuo
Journal:  Br J Pharmacol       Date:  2018-01-11       Impact factor: 8.739

3.  VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.

Authors:  Carmen Del Rio; Irene Cantarero; Belén Palomares; María Gómez-Cañas; Javier Fernández-Ruiz; Carolina Pavicic; Adela García-Martín; Maria Luz Bellido; Rafaela Ortega-Castro; Carlos Pérez-Sánchez; Chary López-Pedrera; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2018-08-23       Impact factor: 8.739

Review 4.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

5.  Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy.

Authors:  Chuanrui Ma; Wenwen Zhang; Xiaoxiao Yang; Ying Liu; Lipei Liu; Ke Feng; Xiaomeng Zhang; Shu Yang; Lei Sun; Miao Yu; Jie Yang; Xiaoju Li; Wenquan Hu; Robert Q Miao; Yan Zhu; Luyuan Li; Jihong Han; Yuanli Chen; Yajun Duan
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

6.  Short lipopeptides specifically inhibit the growth of Propionibacterium acnes with dual antibacterial and anti-inflammatory action.

Authors:  Guang Yang; Jingyu Wang; Shengsheng Lu; Zhao Chen; Sheng Fan; Daiwei Chen; Huanxin Xue; Wenyuan Shi; Jian He
Journal:  Br J Pharmacol       Date:  2019-04-15       Impact factor: 8.739

7.  LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.

Authors:  Rong Fu; Yi-Wei Zhang; Hong-Mei Li; Wen-Cong Lv; Li Zhao; Qing-Long Guo; Tao Lu; Stephen J Weiss; Zhi-Yu Li; Zhao-Qiu Wu
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

8.  PEP06 polypeptide 30 exerts antitumour effect in colorectal carcinoma via inhibiting epithelial-mesenchymal transition.

Authors:  Siming Yu; Linna Li; Wei Tian; Dan Nie; Wei Mu; Fang Qiu; Yu Liu; Xinghan Liu; Xiaofeng Wang; Zhimin Du; Wen-Feng Chu; Baofeng Yang
Journal:  Br J Pharmacol       Date:  2018-06-15       Impact factor: 8.739

Review 9.  Hydrogen sulfide and dermatological diseases.

Authors:  Silvia A Coavoy-Sánchez; Soraia K P Costa; Marcelo N Muscará
Journal:  Br J Pharmacol       Date:  2019-06-18       Impact factor: 8.739

10.  Nicotinic ACh receptor α7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3.

Authors:  Dong-Jie Li; Jie Tong; Fei-Yan Zeng; Mengqi Guo; Yong-Hua Li; Hongbo Wang; Pei Wang
Journal:  Br J Pharmacol       Date:  2018-11-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.